U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Efficacy of Monoclonal Antibodies in the Context of Rapidly Evolving SARS-CoV-2 Variants - 12/15/2022
  1. News & Events for Human Drugs

Virtual | Virtual

Event Title
Efficacy of Monoclonal Antibodies in the Context of Rapidly Evolving SARS-CoV-2 Variants
December 15, 2022


Date:
December 15, 2022

Time: 13:00-17:00 Central European Time | 7:00 AM-11:00 AM United States EST

OBJECTIVES

This meeting will be held in virtual format only. FDA and EMA seek to bring together scientists, clinicians, industry representatives and regulators to discuss alternative strategies to support the development of novel monoclonal antibody therapies including those based on prototype products that have demonstrated safety and efficacy in clinical trials.   
 
Note: This meeting is intended for experts in the field and/or people actively involved in the topic of the meeting.

REGISTRATION:

This meeting will be held in virtual format only. Advanced registration is required for online observer attendance. To register for this workshop and receive the meeting link, please use the registration link.

MEETING MATERIALS

The full agenda and summary report are available.


Back to Top